ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary

ADC Therapeutics SA

03/08/2021 17:13

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss of 96 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 86 cents per share.
* Revenue was $3.76 million​;  analysts expected $2.23 million. 
* ADC Therapeutics SA's reported EPS for the quarter was a loss
of 95 cents​.
* The mean earnings estimate of analysts had risen by about 0.9%
in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate 
* ADC Therapeutics SA shares had fallen by 14.9% this
quarter and lost 35.3% so far this year.
* The company reported a quarterly loss of $72.57 million.
* Wall Street's median 12-month price target for ADC
Therapeutics SA is $48.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 3 at 04:13 p.m.  ​All
figures in US dollars unless otherwise stated